APR Applied Pharma Science Research

Applied Pharma Research is a Swiss specialty pharmaceutical company focused on developing, manufacturing, licensing, and commercializing science-driven products for niche and rare diseases. The company combines formulation and drug-delivery expertise with proprietary platforms including Physiomimic for prolonged-release amino-acid formulations and Tehclo for hypochlorous-acid-based wound care products. Its portfolio spans marketed products such as PKU GOLIKE and Nexodyn, as well as development-stage assets including APR TD011 for epidermolysis bullosa. APR also provides vertically integrated contract development and analytical services to third parties. The company operates internationally through licensing partners and selected direct commercial operations in Europe. Since 2021, it has operated as a wholly owned subsidiary of Relief Therapeutics.